Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Prostatic Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Recurrence 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Neoplasm Metastasis 1Lymphatic Diseases 1Lung Neoplasms 1Burkitt Lymphoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 217Rituximab 110Etoposide 99Peripheral Blood Stem Cell Transplantation 93Vincristine 91Filgrastim 91Methotrexate 90Cytarabine 90fludarabine phosphate 84Radiotherapy 67Doxorubicin 67Prednisone 66Dexamethasone 57Cyclosporine 53Mycophenolic Acid 52Whole-Body Irradiation 49Busulfan 46Melphalan 44blinatumomab 43fludarabine 41Tacrolimus 41Antilymphocyte Serum 40Methylprednisolone 39merphos 35Calcium Dobesilate 34Leucovorin 33Granulocyte Colony-Stimulating Factor 30Mercaptopurine 26dexamethasone acetate 25dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Burkitt Lymphoma × sepantronium × Clear all
NCT05263583 2025-01-14

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

Cothera Bioscience, Inc

Phase 2 Active not recruiting
14 enrolled
Lymphoid

Burkitt Lymphoma, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡